Scarica l'app Stockscreener
202.91
4.05%
-8.57
Dopo l'orario di chiusura:
202.91
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$211.48
Aprire:
$211.48
Volume 24 ore:
273.33K
Relative Volume:
1.27
Capitalizzazione di mercato:
$4.05B
Reddito:
$268.09M
Utile/perdita netta:
$124.45M
Rapporto P/E:
34.78
EPS:
5.8347
Flusso di cassa netto:
$38.05M
1 W Prestazione:
+0.50%
1M Prestazione:
+10.38%
6M Prestazione:
+22.42%
1 anno Prestazione:
+92.11%
Intervallo 1D:
$200.69
$214.80
Intervallo di 1 settimana:
$196.17
$227.92
Portata 52W:
$93.58
$227.92
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Nome
Ligand Pharmaceuticals Inc
Settore
Industria
Telefono
858-550-7500
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
202.91 | 4.05B | 268.09M | 124.45M | 38.05M | 5.8347 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Iniziato | BofA Securities | Buy |
| 2025-12-09 | Iniziato | Citigroup | Buy |
| 2025-04-10 | Iniziato | Stifel | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Ripresa | Stephens | Overweight |
| 2021-02-04 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-06 | Iniziato | Barclays | Overweight |
| 2020-03-24 | Downgrade | Argus | Buy → Hold |
| 2020-03-10 | Iniziato | Guggenheim | Neutral |
| 2020-02-06 | Iniziato | The Benchmark Company | Buy |
| 2019-09-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-03 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-06 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-29 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-11 | Reiterato | Argus | Buy |
| 2018-08-17 | Iniziato | Goldman | Neutral |
| 2018-08-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Iniziato | Argus | Buy |
| 2017-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-05 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-05 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Iniziato | Sidoti | Buy |
| 2016-03-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Fresh Analyst Coverage Puts Ligand Pharmaceuticals (LGND) Royalty Model And Valuation In The Spotlight - simplywall.st
LIGAND PHARMACEUTICALS CFO Sells Shares - TradingView
How Bank of America’s Royalty-Focused Coverage At Ligand Pharmaceuticals (LGND) Has Changed Its Investment Story - simplywall.st
Assessing Ligand Pharmaceuticals (LGND) Valuation After Bank Of America’s New Buy Rating - Yahoo Finance
How a broad sell-off rattled top 3% breakout stock Ligand Pharma - MSN
LIGAND PHARMACEUTICALS INCORPORATED (LGND) - MSN
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Is It Too Late To Consider Ligand Pharmaceuticals (LGND) After A 105% One-Year Surge? - simplywall.st
Ligand Pharmaceuticals is a low-risk way to bet on biopharma growth: Analyst - MSN
Octavio Espinoza sells shares under 10b5-1 plan (LGND) - Stock Titan
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Up 6.9%What's Next? - MarketBeat
Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst - Benzinga
Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst - Benzinga
Ligand Pharmaceuticals offers high-margin exposure to biopharma growth, BofA says - Yahoo! Finance Canada
BofA Securities Initiates Ligand Pharmaceuticals at Buy With $244 Price Target - marketscreener.com
Bofa Global Research announced that it has initiated coverage of Ligand Pharmaceuticals Inc. for the first time, assigning it a "Buy" rating. - Bitget
Ligand stock gains new Buy from BofA (LGND:NASDAQ) - Seeking Alpha
Ligand Pharmaceuticals (LCTX) raises ATM ceiling to $60M with B. Riley - Stock Titan
LGND: B of A Securities Initiates Coverage with Buy Rating and $244 PT | LGND Stock News - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Now Covered by Analysts at Bank of America - MarketBeat
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Ligand Pharmaceuticals stock hits 52-week high at $213.02 By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Sets New 1-Year HighStill a Buy? - MarketBeat
How The Ligand Pharmaceuticals (LGND) Story Is Shifting Around QTORIN And Royalty Growth - Yahoo Finance
Ligand Pharmaceuticals (NASDAQ:LGND) Rating Lowered to Hold at Wall Street Zen - MarketBeat
Ligand Pharmaceuticals CLO Reardon sells $1m in shares - Investing.com India
Ligand Pharmaceuticals CFO sells $2.76 million in shares By Investing.com - Investing.com Australia
Ligand Pharmaceuticals CLO Reardon sells $1m in shares By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals CFO sells $2.76 million in shares - Investing.com
Ligand Pharmaceuticals (NASDAQ:LGND) CFO Sells $2,762,856.09 in Stock - MarketBeat
Andrew Reardon Sells 5,000 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat
Ligand Pharmaceuticals Executives Sell Shares Worth Over $3.7 Million - TradingView
Planned LGND insider sale: Ligand (LGND) CLO sells 5,000 shares - Stock Titan
Ligand Pharmaceuticals director Sabba sells $409k in shares - Investing.com
Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells $409,851.00 in Stock - MarketBeat
Ligand Pharmaceuticals director Sabba sells $409k in shares By Investing.com - Investing.com Canada
Citigroup Inc. Trims Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals director sells $93k in stock - Investing.com India
Ligand Pharmaceuticals director sells $93k in stock By Investing.com - Investing.com Nigeria
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceutica - GuruFocus
Ligand Pharma (LGND) Earnings Call Transcript - AOL.com
Insider Selling: Ligand Pharmaceuticals (NASDAQ:LGND) Director Sells 467 Shares of Stock - MarketBeat
Ligand Pharmaceuticals (LGND) Is Up 8.1% After Swinging to Profit and Filing New Equity ShelfWhat's Changed - simplywall.st
[144] LIGAND PHARMACEUTICALS INC SEC Filing - Stock Titan
Ligand to Participate in March Investor Conferences - The Manila Times
Ligand plans three March investor appearances in Miami, Dana Point, NYC - Stock Titan
Ligand Pharmaceuticals (LGND): Investor Outlook With 20.74% Potential Upside - DirectorsTalk Interviews
LGND: 2025 Results & Focus on Qtorin - Yahoo Finance
Ligand Pharmaceuticals (LGND) Is Up 7.8% After Swing to Profit and New ATM Offering Filed – Has The Bull Case Changed? - Yahoo Finance
Expert Outlook: Ligand Pharmaceuticals Through The Eyes Of 5 Analysts - Sahm
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):